Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Atossa Therapeutics Inc (ATOS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.02-4.72%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ATOS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital allocation through equity offerings | It raised capital through equity offerings to support operations. | Intact | fails to raise sufficient capital to sustain operations through FY26 | Qualitative: Capital raised via $4.5M offering (Jun) and CVR issuance (Oct) ATOS raised capital through a $4.5M stock offering in June and issued stapled CVRs in October to support operations. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative development-stage biotechnology business, not a proven compounder. The long-term thesis is in a watch state: recent signals improved mildly, but confidence is low and the company remains loss-making with high risk.
The evidence does not provide a valuation measure or clear account of what the market already assumes, so whether ATOS is cheap or expensive versus peers cannot be assessed. The recent decline in share performance alongside results below the industry cohort suggests expectations may be cautious, but the evidence is limited.
Over the multi-year view, progress depends on advancing (Z)-endoxifen in oncology and rare diseases; trial enrollment was completed in 2026-Q2, and management has kept this priority for two quarters. Equity offerings raised $4.5 million upfront in that quarter, with potential total proceeds of $16.5 million, while the business remains loss-making. Near term, the recent earnings beat is positive, but a smaller company in a high-miss-rate industry faces meaningful risk at its next report.
The thesis hinges on continued development progress and whether the clinical program can move forward while the company supports its work with available capital. A guidance cut would be a negative signal, while weaker employment data could weigh on cyclical healthcare names; continued strength among sector bellwethers could support sector sentiment. These external signals are not proof of ATOS-specific progress.
For the next 1 to 3 years, ATOS is a low-confidence, high-risk development story with some evidence of execution progress, but losses and uncertain near-term results leave the long-term thesis unproven. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Atossa is working to settle patent disputes and clarify its strategy in 2026. |
| Recovered |
| patent disputes remain unresolved or escalate through FY26 |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Convert strategic clarity into measurable progress in 2026 | A primary condition in Atossa Therapeutics Inc's published investment case. The stated target is show measurable progress on strategic goals throughout FY26. | Improving | fails to show measurable strategic progress throughout FY26 | Qualitative progress: 2 earnings beats, CVR issuance, but $4.5M dilution Q1/Q2 earnings beats, CVR issuance, $4.5M stock offering, and breast cancer development challenges reported in 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.00 → $-2.78 · observed estimates
$0.08B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-07-25 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-07-26 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-07-27 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-07-28 | $-4.38 | $0 | 1 / 3 |
| 2026-07-29 | $-4.38 | $0 | 1 / 3 |
| 2026-07-30 | $-4.38 | $0 | 1 / 3 |
| 2026-07-31 | $-4.38 | $0 | 1 / 3 |
| 2026-08-01 | $-4.38 | $0 | 1 / 3 |
| 2026-08-02 | $-4.38 | $0 | 1 / 3 |
| 2026-08-03 | $-4.38 | $0 | 1 / 3 |
| 2026-08-04 | $-4.38 | $0 | 1 / 3 |
| 2026-08-05 | $-4.38 | $0 | 1 / 3 |
| 2026-08-06 | $-4.38 | $0 | 1 / 3 |
| 2026-08-07 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-08-08 | $-4.38 | $0 | 1 / 3 |
| 2026-08-09 | $-4.38 | $0 | 1 / 3 |
| 2026-08-10 | $-4.38 | $0 | 1 / 3 |
| 2026-08-11 | $-4.38 | $0 | 1 / 3 |
| 2026-08-12 | $-4.38 | $0 | 1 / 3 |
| 2026-08-13 | $-4.38 | $0 | 1 / 3 |
| 2026-08-14 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-08-15 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-08-16 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-08-17 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-08-18 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-08-19 | $-3.00 | $82,353,500 | 2 / 3 |
| 2026-08-20 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-21 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-22 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-23 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-24 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-25 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-26 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-27 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-28 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-29 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-30 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-08-31 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-01 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-02 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-03 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-04 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-05 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-06 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-07 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-08 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-09 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-10 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-11 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-12 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-13 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-14 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-15 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-16 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-17 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-18 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-19 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-20 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-21 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-22 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-23 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-24 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-25 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-26 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-27 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-28 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-29 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-09-30 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-10-01 | $-2.52 | $82,353,500 | 2 / 3 |
| 2026-10-02 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-03 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-04 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-05 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-06 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-07 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-08 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-09 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-10 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-11 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-12 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-13 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-14 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-15 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-16 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-17 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-18 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-19 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-20 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-21 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-22 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-23 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-24 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-25 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-26 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-27 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-28 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-29 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-30 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-10-31 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-11-01 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-11-02 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-11-03 | $-2.78 | $82,353,500 | 2 / 3 |
| 2026-11-04 | $-2.78 | $82,353,500 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.